Embecta Corp

NASDAQ EMBC

Download Data

Embecta Corp Operating Income to Total Debt 2 year CAGR for the quarter ending March 31, 2024: -20.19%

Embecta Corp Operating Income to Total Debt 2 year CAGR is -20.19% for the quarter ending March 31, 2024. The operating income to total debt ratio measures the ability of a company's operating income to cover its total debt obligations. It is calculated by dividing the operating income by the total debt. This ratio provides insights into the company's ability to generate income from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating income relative to the level of debt, suggesting potential financial strength and debt servicing capability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Embecta Corp Operating Income to Total Debt for the quarter ending March 31, 2023 was 0.03, a -50.63% change year over year.
  • Embecta Corp Operating Income to Total Debt for the quarter ending March 31, 2022 was 0.07.
NASDAQ: EMBC

Embecta Corp

CEO Mr. Devdatt Kurdikar
IPO Date April 1, 2022
Location United States
Headquarters 300 Kimball Drive, Parsippany, NJ, United States, 07054
Employees 2,200
Sector Healthcare
Industry Medical instruments & supplies
Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

AKYA

Akoya Biosciences Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email